Nuformix plc (LON:NFX – Get Free Report) shares traded up 18.6% during trading on Monday . The company traded as high as GBX 0.07 ($0.00) and last traded at GBX 0.07 ($0.00). 65,650 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 5,787,441 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Price Performance
The company has a current ratio of 1.12, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The firm has a market cap of £573,517.00, a price-to-earnings ratio of -1.63 and a beta of 1.22. The company has a 50 day moving average of GBX 0.13 and a 200 day moving average of GBX 0.17.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- 5 discounted opportunities for dividend growth investors
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
